



Parg Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP7283a

Specification

Parg Antibody (N-term) Blocking Peptide - Product Information

Primary Accession <u>Q86W56</u>

Parg Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 670:8505

Other Names

Poly(ADP-ribose) glycohydrolase, PARG

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP7283a was selected from the N-term region of human Parg. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Parg Antibody (N-term) Blocking Peptide - Protein Information

Name PARG

{ECO:0000303|PubMed:14527731, ECO:0000312|HGNC:HGNC:8605}

Parg Antibody (N-term) Blocking Peptide - Background

Poly(ADP-ribose) glycohydrolase (PARG) is the major enzyme responsible for the catabolism of poly(ADP-ribose), a reversible covalent-modifier of chromosomal proteins. The protein is found in many tissues and may be subject to proteolysis generating smaller, active products.

Parg Antibody (N-term) Blocking Peptide - References

Meyer,R.G., Exp. Cell Res. 313 (13), 2920-2936 (2007)Fisher,A.E., Mol. Cell. Biol. 27 (15), 5597-5605 (2007)Keil,C., J. Biol. Chem. 281 (45), 34394-34405 (2006)



Function

Poly(ADP-ribose) glycohydrolase that degrades poly(ADP- ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP- ribose) (PubMed: 15450800, PubMed:21892188, PubMed: tations/23102699" target=" blank">23102699, PubMed:23474714, PubMed:33186521). PARG acts both as an endo- and exoglycosidase, releasing poly(ADP-ribose) of different length as well as ADP-ribose monomers (PubMed:23102699. PubMed:23481255). It is however unable to cleave the ester bond between the terminal ADP-ribose and ADP-ribosylated residues, leaving proteins that are mono-ADP- ribosylated (PubMed: 21892188, PubMed:23474714, PubMed:33186521). Poly(ADP-ribose) is synthesized after DNA damage is only present transiently and is rapidly degraded by PARG (PubMed:23102699). Required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress, while it is not required for recovery from transient replicative stress (PubMed:24906880). Responsible for the prevalence of mono-ADP-ribosylated proteins in cells, thanks to its ability to degrade poly(ADP-ribose) without cleaving the terminal protein-ribose bond (PubMed:<a hr



ef="http://www.uniprot.org/citations/33186 521" target=" blank">33186521). Required for retinoid acid- dependent gene transactivation, probably by removing poly(ADP-ribose) from histone demethylase KDM4D, allowing chromatin derepression at RAR- dependent gene promoters (PubMed:23102699). Involved in the synthesis of ATP in the nucleus, together with PARP1, NMNAT1 and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257).

Cellular Location

[Isoform 1]: Nucleus Note=Colocalizes with PCNA at replication foci (PubMed:21398629) Relocalizes to the cytoplasm in response to DNA damage (PubMed:16460818). [Isoform 3]: Cytoplasm [Isoform 5]: Mitochondrion matrix

Tissue LocationUbiquitously expressed.

Parg Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides